Gil D Rabinovici

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4132047/publications.pdf

Version: 2024-02-01

220 papers	25,294 citations	14124 69 h-index	9118 149 g-index
228 all docs	228 docs citations	228 times ranked	19784 citing authors

#	Article	IF	Citations
1	The Rapid Naming Test: Development and initial validation in typically aging adults. Clinical Neuropsychologist, 2022, 36, 1822-1843.	1.5	7
2	Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimerâ€™s disease. Brain, 2022, 145, 713-728.	3.7	43
3	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.4	42
4	rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. NeuroImage, 2022, 246, 118775.	2.1	17
5	Research Criteria for the Behavioral Variant of Alzheimer Disease. JAMA Neurology, 2022, 79, 48.	4.5	44
6	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
7	Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimerâ€™s disease. Brain, 2022, 145, 744-753.	3.7	25
8	Subcortical Neuronal Correlates of Sleep in Neurodegenerative Diseases. JAMA Neurology, 2022, 79, 498.	4.5	20
9	The severity of neuropsychiatric symptoms is higher in earlyâ€onset than lateâ€onset Alzheimerâ€™s disease. European Journal of Neurology, 2022, 29, 957-967.	1.7	16
10	Regional AÎ²-tau interactions promote onset and acceleration of Alzheimerâ€™s disease tau spreading. Neuron, 2022, 110, 1932-1943.e5.	3.8	64
11	Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. JAMA Network Open, 2022, 5, e228392.	2.8	44
12	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	2.8	18
13	Multi-Modal Biomarkers of Repetitive Head Impacts and Traumatic Encephalopathy Syndrome: A Clinicopathological Case Series. Journal of Neurotrauma, 2022, 39, 1195-1213.	1.7	16
14	Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. Neurology, 2022, 99, .	1.5	10
15	Rare APOE Missense Variantsâ€”Can We Overcome APOE Îµ4 and Alzheimer Disease Risk?. JAMA Neurology, 2022, 79, 649.	4.5	4
16	The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. Journal of Nuclear Medicine, 2022, 63, 13S-19S.	2.8	34
17	Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials. Journal of Nuclear Medicine, 2022, 63, 830-832.	2.8	7
18	Right temporal degeneration and socioemotional semantics: semantic behavioural variant frontotemporal dementia. Brain, 2022, 145, 4080-4096.	3.7	34

#	Article	IF	Citations
19	Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimerâ€™s disease. Brain, 2022, 145, 4489-4505.	3.7	23
20	Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology, 2021, 96, e650-e661.	1.5	73
21	Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease. JAMA Neurology, 2021, 78, 143.	4.5	16
22	Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment. JAMA Neurology, 2021, 78, 197.	4.5	54
23	Diagnostic Accuracy of Amyloid versus ¹⁸Fâ€Fluorodeoxyglucose Positron Emission Tomography in <scp>Autopsyâ€Confirmed</scp> Dementia. Annals of Neurology, 2021, 89, 389-401.	2.8	34
24	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	3.3	27
25	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimerâ€™s Disease Continuum. Cerebral Cortex, 2021, 31, 1-14.	1.6	34
26	Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults. Brain Imaging and Behavior, 2021, 15, 2417-2425.	1.1	9
27	Detecting Alzheimerâ€™s disease biomarkers with a brief tablet-based cognitive battery: sensitivity to AÎ² and tau PET. Alzheimer's Research and Therapy, 2021, 13, 36.	3.0	10
28	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168.	3.3	18
29	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, 1329-1341.	0.4	34
30	Crossed cerebellar diaschisis on¹⁸F-FDG PET: Frequency across neurodegenerative syndromes and association with¹¹C-PIB and¹⁸F-Flortaucipir. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2329-2343.	2.4	9
31	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	2.8	12
32	Comorbid neuropathological diagnoses in early versus late-onset Alzheimerâ€™s disease. Brain, 2021, 144, 2186-2198.	3.7	100
33	New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurology, The, 2021, 20, 222-234.	4.9	214
34	The strategic biomarker roadmap for the validation of Alzheimerâ€™s diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	3.3	22
35	Four distinct trajectories of tau deposition identified in Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 871-881.	15.2	354
36	Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in earlyâ€onset and atypical Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 2009-2019.	0.4	17

#	Article	IF	Citations
37	Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease. JAMA Neurology, 2021, 78, 445.	4.5	33
38	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	0.9	17
39	The Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.4	34
40	Identifying degenerative effects of repetitive head trauma with neuroimaging: a clinically-oriented review. Acta Neuropathologica Communications, 2021, 9, 96.	2.4	22
41	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2295-2305.	3.3	41
42	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurology, The, 2021, 20, 484-496.	4.9	396
43	Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California. JAMA Neurology, 2021, 78, 657.	4.5	62
44	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
45	Dominantly inherited Alzheimerâ€™s disease: a compass for drug development. Nature Medicine, 2021, 27, 1148-1150.	15.2	3
46	Evaluation of [¹⁸F]-JNJ-64326067-AAA tau PET tracer in humans. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3302-3313.	2.4	15
47	Controversy and Progress in Alzheimerâ€™s Disease â€” FDA Approval of Aducanumab. New England Journal of Medicine, 2021, 385, 771-774.	13.9	101
48	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	4.5	148
49	Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females. Neurobiology of Aging, 2021, 105, 86-98.	1.5	29
50	Professional Soccer and Dementia Riskâ€”The Ugly Side of the Beautiful Game. JAMA Neurology, 2021, 78, 1049.	4.5	5
51	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
52	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	3.3	10
53	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.5	84
54	Relationship Between Tau and Cognition in the Evolution of Alzheimerâ€™s Disease: New Insights from Tau PET. Journal of Nuclear Medicine, 2021, 62, 612-613.	2.8	16

#	Article	IF	Citations
55	Longitudinal Earlyâ€onset Alzheimerâ€™s Disease Study (LEADS) genetic screening: Initial results. Alzheimer's and Dementia, 2021, 17, e056493.	0.4	0
56	Inâ€depth investigation in tau positron emission tomography tracers offâ€target binding with voxelâ€toâ€voxel correlation analysis of tau and amyloid PET signal to histological iron and tau deposit in nonâ€Alzheimer tauopathies. Alzheimer's and Dementia, 2021, 17, .	0.4	0
57	Diagnostic applications of tau PET. Alzheimer's and Dementia, 2021, 17, .	0.4	0
58	White matter hyperintensities and regional tauâ€PET signal independently contribute to cognitive deficits in symptomatic patients on the Alzheimerâ€™s disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	0
59	Headâ€toâ€head comparison of [¹⁸ F]Flortaucipir and amyloid PET visual reads for differential diagnosis: An international, multiâ€center study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
60	Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 215.	4.5	81
61	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.4	73
62	Plasma biomarkers of astrocytic and neuronal dysfunction in earlyâ€and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 681-695.	0.4	143
63	Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia. JAMA Neurology, 2020, 77, 358.	4.5	14
64	Prospective longitudinal atrophy in Alzheimerâ€™s disease correlates with the intensity and topography of baseline tau-PET. Science Translational Medicine, 2020, 12, .	5.8	353
65	Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy. JAMA Neurology, 2020, 77, 517.	4.5	43
66	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
67	Predicting amyloid status using selfâ€report information from an online research and recruitment registry: The Brain Health Registry. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12102.	1.2	2
68	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. Alzheimer's Research and Therapy, 2020, 12, 148.	3.0	17
69	BHAâ€CS: A novel cognitive composite for Alzheimer's disease and related disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12042.	1.2	12
70	Validation of online functional measures in cognitively impaired older adults. Alzheimer's and Dementia, 2020, 16, 1426-1437.	0.4	20
71	Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage1. Journal of Alzheimer's Disease, 2020, 78, 265-276.	1.2	43
72	Effects of bilingualism on age at onset in two clinical Alzheimer's disease variants. Alzheimer's and Dementia, 2020, 16, 1704-1713.	0.4	10

#	Article	IF	Citations
73	Chronic Traumatic Encephalopathy: A Comparison with Alzheimer's Disease and Frontotemporal Dementia. Seminars in Neurology, 2020, 40, 394-410.	0.5	7
74	Comparison of 18 Fâ€Flortaucipir visual assessment, SUVR quantification and CSF pTau for defining Tâ€status in the AT(N) framework. Alzheimer's and Dementia, 2020, 16, e037276.	0.4	0
75	Amyloid and tau PET in sporadic earlyâ€onset Alzheimerâ€™s disease: Preliminary results from LEADS. Alzheimer's and Dementia, 2020, 16, e041613.	0.4	2
76	Glucose metabolism mainly reflects local atrophy and tau pathology at symptomatic stages of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043968.	0.4	1
77	Heterogeneous distribution of pathology in behavioral variant Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e044830.	0.4	1
78	Impact of cortical and subcortical atrophy in the diagnosis and prognosis of bvFTD: A multicenter longitudinal study. Alzheimer's and Dementia, 2020, 16, e044984.	0.4	0
79	Spatiotemporal imaging phenotypes of tau pathology in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045612.	0.4	5
80	Comparative diagnostic performance of plasma Pâ€tau217 and Pâ€tau181 in Alzheimerâ€™s disease and frontotemporal lobar degeneration and correlations with [18F]Flortaucipirâ€PET uptake. Alzheimer's and Dementia, 2020, 16, e045755.	0.4	0
81	Predicting amyloid status using remote online selfâ€report and cognitive assessment: The Brain Health Registry. Alzheimer's and Dementia, 2020, 16, e045932.	0.4	1
82	Colocalization of atrophy and tau improves AI classification of Alzheimer phenotypical variants. Alzheimer's and Dementia, 2020, 16, e046258.	0.4	1
83	Evaluation of a visual interpretation method for tauâ€PET with ¹⁸ Fâ€flortaucipir. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12133.	1.2	17
84	18F-flortaucipir PET to autopsy comparisons in Alzheimerâ€™s disease and other neurodegenerative diseases. Brain, 2020, 143, 3477-3494.	3.7	100
85	Symptomatic amyloidâ€related imaging abnormalities in an APOE Îµ4/Îµ4 patient treated with aducanumab. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12101.	1.2	41
86	Neurophysiological signatures in Alzheimerâ€™s disease are distinctly associated with TAU, amyloid-Î² accumulation, and cognitive decline. Science Translational Medicine, 2020, 12, .	5.8	59
87	Longitudinal structural and metabolic changes in frontotemporal dementia. Neurology, 2020, 95, e140-e154.	1.5	39
88	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	4.5	80
89	Diagnostic value of plasma phosphorylated tau181 in Alzheimerâ€™s disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	15.2	471
90	Non-coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases. American Journal of Human Genetics, 2020, 106, 632-645.	2.6	50

#	Article	IF	Citations
91	AÎ² deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimerâ€™s disease. Science Advances, 2020, 6, eaaz2387.	4.7	202
92	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	4.9	121
93	Alzheimerâ€™s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation. Acta Neuropathologica, 2019, 138, 597-612.	3.9	75
94	Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. NeuroImage: Clinical, 2019, 24, 102025.	1.4	53
95	Cortical developmental abnormalities in logopenic variant primary progressive aphasia with dyslexia. Brain Communications, 2019, 1, fcz027.	1.5	11
96	The Rise of Pseudomedicine for Dementia and Brain Health. JAMA - Journal of the American Medical Association, 2019, 321, 543.	3.8	31
97	Polygenic hazard score, amyloid deposition and Alzheimerâ€™s neurodegeneration. Brain, 2019, 142, 460-470.	3.7	63
98	18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer's Research and Therapy, 2019, 11, 13.	3.0	121
99	Association of Early-Onset Alzheimer Disease With Elevated Low-Density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB. JAMA Neurology, 2019, 76, 809.	4.5	94
100	Alzheimerâ€™s pathology targets distinct memory networks in the ageing brain. Brain, 2019, 142, 2492-2509.	3.7	131
101	Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. NeuroImage: Clinical, 2019, 23, 101848.	1.4	73
102	Atypical clinical features associated with mixed pathology in a case of non-fluent variant primary progressive aphasia. Neurocase, 2019, 25, 39-47.	0.2	8
103	Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 1286.	3.8	391
104	ICâ€Pâ€012: PREDICTORS OF Î²â€AMYLOID POSITIVITY IN COGNITIVELY IMPAIRED PATIENTS: DATA FROM THE IMAGING DEMENTIA â€" EVIDENCE FOR AMYLOID SCANNING (IDEAS) STUDY. Alzheimer's and Dementia, 2019, 15, P21.	0.4	1
105	ICâ€Pâ€097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING. Alzheimer's and Dementia, 2019, 15, P84.	0.4	0
106	Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease. JAMA Internal Medicine, 2019, 179, 1736.	2.6	3
107	Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Annals of Neurology, 2019, 85, 229-240.	2.8	198
108	Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar?. NeuroImage: Clinical, 2019, 21, 101628.	1.4	22

#	Article	IF	Citations
109	Dissecting the genetic relationship between cardiovascular risk factors and Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 209-226.	3.9	100
110	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.4	155
111	Late-onset Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 14-33.	0.4	70
112	Legal and Policy Challenges to Addressing Cognitive Impairment in Federal Officials. JAMA Neurology, 2019, 76, 392.	4.5	1
113	A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date. Journal of Neurotrauma, 2018, 35, 2015-2024.	1.7	25
114	Prevalence of Mathematical and Visuospatial Learning Disabilities in Patients With Posterior Cortical Atrophy. JAMA Neurology, 2018, 75, 728.	4.5	46
115	Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology, 2018, 90, e1047-e1056.	1.5	36
116	Metabolic brain networks in aging and preclinical Alzheimer's disease. NeuroImage: Clinical, 2018, 17, 987-999.	1.4	29
117	Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging. Alzheimer Disease and Associated Disorders, 2018, 32, 35-42.	0.6	5
118	CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology, 2018, 90, e273-e281.	1.5	75
119	Associations between [¹⁸ F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology, 2018, 90, e282-e290.	1.5	113
120	Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurology, 2018, 75, 342.	4.5	76
121	Multiproteinopathy, neurodegeneration and old age: a case study. Neurocase, 2018, 24, 1-6.	0.2	2
122	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
123	Visuospatial Functioning in the Primary Progressive Aphasias. Journal of the International Neuropsychological Society, 2018, 24, 259-268.	1.2	53
124	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. NeuroImage: Clinical, 2018, 17, 452-464.	1.4	126
125	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
126	Associations Between Tau, Î²-Amyloid, and Cognition in Parkinson Disease. JAMA Neurology, 2018, 75, 227.	4.5	57

#	Article	IF	Citations
127	Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging. Journal of Neuroscience, 2018, 38, 530-543.	1.7	201
128	Polygenic hazard score: an enrichment marker for Alzheimerâ€™s associated amyloid and tau deposition. Acta Neuropathologica, 2018, 135, 85-93.	3.9	80
129	O3â€13â€01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1054.	0.4	0
130	PL-05-01: PATHOGENESIS OF ALZHEIMER'S DISEASE: WHAT HAVE WE LEARNED FROM NEUROIMAGING?. , 2018, 14, P1635-P1635.		0
131	P1â€597: AMYLOID NEUROIMAGING AND GENETICS INITIATIVE: IMPLEMENTING DNA COLLECTION USING NOVEL CONSENTING APPROACHES FOR AN IDEAS ADDâ€ON STUDY. Alzheimer's and Dementia, 2018, 14, P566.	0.4	0
132	ICâ€Pâ€110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P94.	0.4	0
133	O1â€01â€05: DISTINCT NEURAL OSCILLATION ABNORMALITIES ASSOCIATED WITH AMYLOIDâ€BETA AND TAU IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P213.	0.4	0
134	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
135	Discriminative Accuracy of [¹⁸F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	3.8	298
136	Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using ¹⁸F-AV1451 Positron Emission Tomography Imaging. JAMA Neurology, 2018, 75, 999.	4.5	85
137	Amyloid involvement in subcortical regions predicts cognitive decline. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2368-2376.	3.3	30
138	Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA. Cortex, 2018, 108, 252-264.	1.1	41
139	Prominent Non-Memory Deficits in Alzheimerâ€™s Disease Are Associated with Faster Disease Progression. Journal of Alzheimer's Disease, 2018, 65, 1029-1039.	1.2	14
140	Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units. Journal of Alzheimer's Disease, 2018, 63, 1025-1033.	1.2	5
141	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Medicine, 2018, 15, e1002487.	3.9	111
142	Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 152-164.	0.9	107
143	Regional correlations between [11 C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. NeuroImage: Clinical, 2017, 13, 130-137.	1.4	50
144	Frontotemporal dementia with the V337M MAPT mutation. Neurology, 2017, 88, 758-766.	1.5	76

#	Article	IF	Citations
145	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 2017, 133, 825-837.	3.9	90
146	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
147	Cognitive subtypes of probable Alzheimer's disease robustly identified inÂfour cohorts. Alzheimer's and Dementia, 2017, 13, 1226-1236.	0.4	59
148	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	2.2	121
149	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	2.2	179
150	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	2.2	1,402
151	Focal cerebral Î²-amyloid angiopathy. Neurology: Clinical Practice, 2017, 7, 444-448.	0.8	2
152	Sleep changes without medial temporal lobe or brain cortical changes in communityâ€dwelling individuals with subjective cognitive decline. Alzheimer's and Dementia, 2017, 13, 783-791.	0.4	43
153	¹⁸Fâ€flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of Neurology, 2017, 82, 622-634.	2.8	148
154	Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimerâ€™s disease. Brain, 2017, 140, 3286-3300.	3.7	472
155	Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain, 2017, 140, 3329-3345.	3.7	226
156	Advances and Gaps in Understanding Chronic Traumatic Encephalopathy. JAMA - Journal of the American Medical Association, 2017, 318, 338.	3.8	9
157	[DTâ€01â€“01]: IMPACT OF AMYLOID PET ON PATIENT MANAGEMENT: EARLY RESULTS FROM THE IDEAS STUDY. Alzheimer's and Dementia, 2017, 13, P1474.	0.4	10
158	Reference Tissueâ€“Based Kinetic Evaluation of ¹⁸F-AV-1451 for Tau Imaging. Journal of Nuclear Medicine, 2017, 58, 332-338.	2.8	94
159	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	1.8	94
160	[S1â€“01â€“01]: AMYLOID AND TAU DEPOSITION ACROSS AGES. Alzheimer's and Dementia, 2017, 13, P170.	0.4	0
161	Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage, 2017, 157, 448-463.	2.1	341
162	Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. PLoS ONE, 2016, 11, e0157218.	1.1	40

#	Article	IF	Citations
163	Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. Canadian Journal of Neurological Sciences, 2016, 43, 503-512.	0.3	27
164	Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimerâ€™s Disease Patient with Presenilin-1 Mutation. Journal of Alzheimer's Disease, 2016, 51, 339-343.	1.2	30
165	Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 15-22.	1.2	29
166	P1â€253: Diagnostic Accuracy of Amyloidâ€•Versus Fdgâ€Pet in Autopsyâ€Confirmed Dementia. Alzheimer's and Dementia, 2016, 12, P506.	0.4	0
167	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
168	PET Imaging of Tau Deposition in the Aging Human Brain. Neuron, 2016, 89, 971-982.	3.8	899
169	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's and Dementia, 2016, 12, 510-515.	0.4	23
170	Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease. JAMA Neurology, 2016, 73, 691.	4.5	151
171	Dynamic relationships between age, amyloid-Î² deposition, and glucose metabolism link to the regional vulnerability to Alzheimerâ€™s disease. Brain, 2016, 139, 2275-2289.	3.7	75
172	Healthy brain connectivity predicts atrophy progression in non-fluent variant of primary progressive aphasia. Brain, 2016, 139, 2778-2791.	3.7	108
173	Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease. Human Brain Mapping, 2016, 37, 4234-4247.	1.9	55
174	Distinct Subtypes of Behavioral Variant Frontotemporal Dementia Based on Patterns of Network Degeneration. JAMA Neurology, 2016, 73, 1078.	4.5	115
175	Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology, 2016, 87, 2016-2025.	1.5	65
176	Timing and significance of pathological features inC9orf72expansion-associated frontotemporal dementia. Brain, 2016, 139, 3202-3216.	3.7	136
177	MCPâ€1 and eotaxinâ€1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 91-97.	1.2	53
178	Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology, 2016, 86, 600-610.	1.5	73
179	Cavum Septum Pellucidum in Retired American Pro-Football Players. Journal of Neurotrauma, 2016, 33, 157-161.	1.7	68
180	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.4	1,318

#	Article	IF	Citations
181	Amyloid biomarkers: pushing the limits of early detection. Brain, 2016, 139, 1008-1010.	3.7	5
182	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimerâ€™s disease. Brain, 2016, 139, 1551-1567.	3.7	833
183	Early-onset Alzheimerâ€™s disease versus frontotemporal dementia: resolution with genetic diagnoses?. Neurocase, 2016, 22, 161-167.	0.2	3
184	Amyloid in dementia associated with familial FTLD: not an innocent bystander. Neurocase, 2016, 22, 76-83.	0.2	12
185	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimerâ€™s disease. Brain, 2016, 139, 2528-2539.	3.7	58
186	IC-P-161: Tau PET with [18 F]AV1451 in non-alzheimer's disease neurodegenerative syndromes. , 2015, 11, P107-P109.		4
187	FTSâ€04â€02: Imaging dementia: Evidence for amyloid scanning (IDEAS)â€”a national study to evaluate the clinical utility of amyloid PET. Alzheimer's and Dementia, 2015, 11, P263.	0.4	4
188	Atrophy patterns in early clinical stages across distinct phenotypes of <scp>A</scp>lzheimer's disease. Human Brain Mapping, 2015, 36, 4421-4437.	1.9	196
189	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain, 2015, 138, 2020-2033.	3.7	319
190	F2-03-01: Tau and amyloid neuroimaging of ad phenotypes. , 2015, 11, P167-P167.		0
191	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.	1.5	49
192	The behavioural/dysexecutive variant of Alzheimerâ€™s disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	3.7	397
193	Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimer's Research and Therapy, 2015, 7, 8.	3.0	32
194	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
195	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	3.8	501
196	The Translational Journey of Brain Î²-Amyloid Imaging. JAMA Neurology, 2015, 72, 265.	4.5	9
197	Evaluating and treating neurobehavioral symptoms in professional American football players. Neurology: Clinical Practice, 2015, 5, 285-295.	0.8	24
198	Loss of functional connectivity is greater outside the default mode network in nonfamilial early-onset Alzheimer's disease variants. Neurobiology of Aging, 2015, 36, 2678-2686.	1.5	72

#	Article	IF	Citations
199	Clinical use of amyloidâ€positron emission tomography neuroimaging: Practical and bioethical considerations. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 358-367.	1.2	33
200	Divergent CSF Â alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 244-250.	0.9	101
201	Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 266-273.	0.9	47
202	IC-P-023: AMYLOID PET HAS GREATER CLINICAL IMPACT THAN FDG PET IN THE DIFFERENTIAL DIAGNOSIS OF AD AND FTD. , 2014, 10, P17-P18.		0
203	Amyloid imaging in atypical dementia. Cmaj, 2014, 186, 695-695.	0.9	2
204	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	4.9	2,657
205	Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. NeuroImage: Clinical, 2014, 4, 508-516.	1.4	59
206	O4-01-03: AMYLOID PET HAS GREATER CLINICAL IMPACT THAN FDG PET IN THE DIFFERENTIAL DIAGNOSIS OF AD AND FTD. , 2014, 10, P249-P249.		0
207	Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimerâ€™s disease. Brain, 2013, 136, 844-858.	3.7	280
208	Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11606-11611.	3.3	105
209	Imaging prodromal FTD. Neurology, 2013, 81, 1282-1283.	1.5	3
210	Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People. JAMA Neurology, 2013, 70, 1512-9.	4.5	139
211	Amyloid imaging, risk disclosure and Alzheimerâ€™s disease: ethical and practical issues. Neurodegenerative Disease Management, 2013, 3, 219-229.	1.2	48
212	Association of Lifetime Cognitive Engagement and Low Î²-Amyloid Deposition. Archives of Neurology, 2012, 69, 623.	4.9	278
213	Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. NeuroImage, 2012, 59, 1152-1160.	2.1	137
214	Corticobasal syndrome: overcoming the artificial divide between disorders of cognition and movement. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 404-404.	0.9	5
215	Relationships between Beta-Amyloid and Functional Connectivity in Different Components of the Default Mode Network in Aging. Cerebral Cortex, 2011, 21, 2399-2407.	1.6	306
216	Sporadic corticobasal syndrome due to FTLD-TDP. Acta Neuropathologica, 2010, 119, 365-374.	3.9	59

#	Article	IF	Citations
217	Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimerâ€™s disease. Brain, 2010, 133, 1352-1367.	3.7	876
218	Frontotemporal Lobar Degeneration. CNS Drugs, 2010, 24, 375-398.	2.7	353
219	Seizures in corticobasal degeneration: A case report. Neurocase, 2009, 15, 352-356.	0.2	12
220	Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimerâ€™s disease. ELife, 0, 11, .	2.8	45